A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions. Results of the AMEthyst Randomized Controlled Trial

JACC: Cardiovascular Interventions

Volumn 1, Issue 3, 2008, Pages 248-257

  Kereiakes, Dean J ^a   Turco, Mark A ^b   Breall, Jeffrey ^c   Farhat, Naim Z ^d   Feldman, Robert L ^e   McLaurin, Brent ^f   Popma, Jeffrey J ^g   Mauri, Laura ^g,h   Zimetbaum, Peter ^h,i   Massaro, Joseph ^h   Cutlip, Donald E ^h,i  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b WASHINGTON ADVENTIST HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d North Ohio Heart Center   (United States)

^e Munroe Regional Med Center   (United States)

^f ANMED HEALTH   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD FILTER; BLOOD VESSEL DIAMETER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT; TREATMENT OUTCOME; VEIN EMBOLISM; VEIN GRAFT DISEASE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONSTRICTION, PATHOLOGIC; CORONARY ARTERY BYPASS; EMBOLISM; EQUIPMENT DESIGN; EQUIPMENT SAFETY; FEMALE; FILTRATION; GRAFT OCCLUSION, VASCULAR; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SAPHENOUS VEIN; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 44949128055     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.03.009     Document Type: Article

References (30)

1. de Feyter P.J. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. Circulation 107 (2003) 2284-2286
2. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28 (1996) 616-626
3. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
4. Keeley E.C., Velez C.A., O'Neill W.W., and Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
5. Weintraub W.S., Jones E.L., Morris D.C., King III S.B., Guyton R.A., and Craver J.M. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 95 (1997) 868-877
6. Hong M.K., Mehran R., Dangas G., et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 100 (1999) 2400-2405
7. Hong M.K., Mehran R., Dangas G., et al. Are we making progress with percutaneous saphenous vein graft treatment?. A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol 38 (2001) 150-154
8. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
9. Piana R.N., Paik G.Y., Moscucci M., et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 89 (1994) 2514-2518
10. Webb J.G., Carere R.G., Virmani R., et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 34 (1999) 468-475
11. Grube E., Gerckens U., Yeung A.C., et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 104 (2001) 2436-2441
12. Gorog D.A., Foale R.A., and Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where?. J Am Coll Cardiol 46 (2005) 1434-1445
13. Baim D.S., Wahr D., George B., et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105 (2002) 1285-1290
14. Stone G.W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108 (2003) 548-553
15. Young J.J., Kereiakes D.J., Rabinowitz A.C., Ammar R., Boucher F.L., and Rogers C. A novel, low-profile filter-wire (Interceptor) embolic protection device during saphenous vein graft stenting. Am J Cardiol 95 (2005) 511-514
16. Stone G.W., Rogers C., Ramee S., et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 40 (2002) 1882-1888
17. van der Zwet P.M., and Reiber J.H. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. J Am Coll Cardiol 24 (1994) 216-224
18. Farrington C.P., and Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9 (1990) 1447-1454
19. Coolong A., Baim D.S., Kuntz R.E., et al. Saphenous vein graft stenting and major adverse cardiac events-a predictive model derived from a pooled analysis of 3958 patients. Circulation 117 (2008) 790-797
20. Giugliano G.R., Kuntz R.E., Popma J.J., Cutlip D.E., and Baim D.S. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 95 (2005) 173-177 21
21. Smith Jr. S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2005) 156-175
22. Kereiakes D.J. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full. Circulation 106 (2002) 3063-3067
23. Rogers C., Huynh R., Seifert P.A., et al. Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation 109 (2004) 1735-1740
24. Salloum J., Reddy B., Vaughan D.E., and Zaho D.X. Elimination of soluble vasoactive factors by the PercuSurge Guardwire distal protection device during percutaneous coronary intervention of saphenous vein graft. (abstr). J Am Coll Cardiol 43 (2004) 71A
25. Mehta S.K., Frutkin A.D., Milford-Beland S., et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 100 (2007) 1114-1118
26. Ellis S.G., Lincoff A.M., Miller D., et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol 32 (1998) 1619-1623
27. Roffi M., Mukherjee D., Chew D.P., et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 106 (2002) 3063-3067
28. Goto S., Tamura N., and Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44 (2004) 316-323
29. Pasceri V., Patti G., Nusca A., et al., for the ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
30. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278